Találati lista | Tudóstér

001-es BibID:	BIBFORM030226
Első szerző:	Ponyi Andrea
Cím:	Cancer-associated myositis : clinical features and prognostic signs / Andrea Ponyi, Tamás Constantin, Miklós Garami, Csilla András, Béla Tállai, Andrea Váncsa, Lajos Gergely, Katalin Dankó
Dátum:	2005
Megjegyzések:	Idiopathic inflammatory myositis is characterized by progressive weakness of the proximal muscles. There is a higher risk of malignancy than in the normal population. The aim of this study was to evaluate the frequency of malignancy among 251 myositis patients. We also compared clinical and immunological characteristics of cancer-associated myositis with primary myositis. There were no malignancies among polymyositis, overlap, or juvenile myositis patients. Twenty-two of ninety dermatomyositis patients also had a malignant disease. Patients with cancer-associated dermatomyositis were significantly older than primary myositis patients and had more severe cutaneous and muscle symptoms. Dysphagia and diaphragmatic involvement were more frequent among cancer-associated patients, while extramuscular features were less frequent. After successful treatment of the malignancy, we were able to manage myositis symptoms. One-year survival rate was significantly better in primary dermatomyositis patients. The subset of cancer-associated myositis differs from primary myositis in many aspects of its clinical and immunological features. Prognosis and life expectancy in cancer-associated myositis patients is determined by the underlying malignant disease. Therefore, age- and sex-specific examinations for detection of an underlying malignancy are important in the management of patients with dermatomyositis.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Annals of the New York Academy of Sciences. - 1051 (2005), p. 64-71. -
További szerzők:	Constantin Tamás Garami Miklós András Csilla (1961-) (onkológus szakorvos) Tállai Béla (1970-) (urológus) Váncsa Andrea (1972-) (orvos) Gergely Lajos (1965-) (belgyógyász, haematológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM001945
Első szerző:	Szekanecz Éva (onkológus szakorvos)
Cím:	Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis : potential adhesion molecules in synovial inflammation? / Szekanecz E., Sándor Z., Antal-Szalmás P., Soós L., Lakos G., Besenyei T., Szentpétery A., Simkovics E., Szántó J., Kiss E., Koch A. E., Szekanecz Z.
Dátum:	2007
Megjegyzések:	Some tumor-associated antigens (TAAs) are expressed on inflammatory cells. We previously detected carcinoembryonic antigen (CEA; CD66) in the rheumatoid (RA) synovium. The production of CEA, CA19-9, CA125, and CA15.3, may be increased in patients with RA, scleroderma, lupus, and Sjogren's syndrome (SS). Some of these TAAs contain sialylated carbohydrate motifs and they are involved in tumor-associated cell adhesion and metastasis. We assessed levels of TAAs in the sera of RA patients and healthy subjects. Serum TAA levels were correlated with disease markers including serum rheumatoid factor (RF), C-reactive protein (CRP), and anti-CCP antibody levels, DAS28, age disease duration. TAAs including CEA, CA15-3, CA72-4, CA125, and CA19-9, and neuron-specific enolase (NSE) were assessed by immunoassay in the sera of 75 patients with RA and 50 age- and sex-matched healthy controls. Normal upper limits for these TAAs were 3.4 microg/L, 25 kU/L, 6.9 kU/L, 35 kU/L, 34 kU/L, and 16.3 microg/L, respectively. There were significantly more RA patients showing abnormally high levels of CA125 (10.8% versus 7.1%), CA19-9 (8.1% versus 0%), and CA15-3 (17.6% versus 14.3%) in comparison to controls (P < 0.05). The mean absolute serum levels of CA125 (23.9 +/- 1.8 versus 16.8 +/- 2.2 kU/L) and CA19-9 (14.2 +/- 1.2 versus 10.5 +/- 1.6 kU/L) were also significantly higher in RA compared to controls (P < 0.05). Among RA patients, serum CEA showed significant correlation with RF (r = 0.270; P < 0.05). None of the assessed TAAs showed any correlation with CRP, anti-CCP, DAS28, age or disease duration. The concentration of some TAAs may be elevated in the sera of patients with established RA in comparison to healthy subjects. CEA, CA19-9, CA125, and CA15-3 contain carbohydrate motifs and thus they may be involved in synovitis-associated adhesive events. Furthermore, some TAAs, such as CEA, may also correlate with prognostic factors, such as serum RF levels.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban rheumatoid arthritis tumor antigens anti-CCP antibody rheumatoid factor carcinoembryonic antigen
Megjelenés:	Annals of the New York Academy of Sciences 1108 (2007), p. 359-371. -
További szerzők:	Sándor Zsuzsa (1980-) (pathológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Soós Lilla Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Besenyei Tímea (1980-) (reumatológus, belgyógyász) Szentpétery Ágnes (1978-) (reumatológus) Simkovics Enikő Szántó János (1949-) (onkológus szakorvos) Kiss Emese (1960-) (belgyógyász, immunológus) Koch, Alisa E. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	elektronikus változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM001953
Első szerző:	Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:	Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus : results from a single center / Tarr T., Gyorfy B., Szekanecz E., Bhattoa H. P., Zeher M., Szegedi G., Kiss E.
Dátum:	2007
Megjegyzések:	As a result of increasing life expectancy of lupus patients, malignant disorders have become major determinants of morbidity and mortality. The objectives of this study were to analyze cancer-associated morbidity and mortality, the type of malignancies in Hungarian lupus patients, and to analyze association with immune-suppressive therapy, disease duration, and age of the patients. Data from 860 systemic lupus erythematosus (SLE) patients were retrospectively analyzed in a study period between 1970 and 2004. Results were compared to data from age- and sex-matched population obtained from the Health for All database, and also to literature data. A total of 37 patients presented with cancer, reflecting 4.3% cancer-associated morbidity. Patients were 47 (20-73) years old at the onset of malignancy, which appeared 13 (1-45) years later than SLE. Cancer prevalence was the highest in the first 5-10 years of lupus. Breast cancer was the most common malignancy (n = 11) followed by gastrointestinal tumors (n = 9), cervix cancer and hematologic malignancies (n = 5 for both), bronchial cancer (n = 4), bladder, skin, and ovarian cancer (n = 1 for each). Standardized incidence ratio was the highest for non-Hodgkin lymphoma (standardized incidence ratio [SIR] 3.5, 95% CI 0.4-12.5) and cervix cancer (SIR 1.7, 95% CI 0.6-4.1). Although 76% of patients with cancer received immune-suppressive therapy besides corticosteroids, no direct correlation could be confirmed between therapy and malignancy. Out of the 164 patients that expired during the study period, 18 were cancer-related. As such the cancer-associated mortality was 11% (18/164). This peaked during the last 4 years of the study period (8/24, 33%). Lupus patients are at high risk for particular types of malignant disorders, highlighting the importance of screening measures and focused patient examination.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban lupus cancer malignancy lymphoma azathioprine chloroquine corticosteroid cyclophosphamide cyclosporin A immunosuppressive agent methotrexate adult aged bladder cancer breast cancer bronchus cancer conference paper controlled study data analysis data base disease association disease duration female gastrointestinal tumor hematologic malignancy human Hungary immunosuppressive treatment incidence male morbidity mortality nonhodgkin lymphoma ovary cancer prevalence retrospective study skin cancer standardization systemic lupus erythematosus uterine cervix cancer Adult Age of Onset Aged Humans Hungary Immunosuppressive Agents Lupus Erythematosus, Systemic Middle Aged Neoplasms Retrospective Studies egyetemen (Magyarországon) készült közlemény
Megjelenés:	Annals of the New York Academy of Sciences 1108 (2007), p. 76-82. -
További szerzők:	Gyorfy Balázs Szekanecz Éva (1968-) (onkológus szakorvos) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI Szerző által megadott URL
Borító:
Saját polcon: